Hyperhomocysteinaemia and vitamin B12 deficiency: The long-term effects in cardiovascular disease

Cardiology

Volumn 107, Issue 1, 2006, Pages 57-62

  Van Oijen, Martijn G H ^a   Vlemmix, Floor ^a   Laheij, Robert J F ^a   Paloheimo, Lea ^b   Jansen, Jan B M J ^a   Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Biohit Oyj   (Finland)

Author keywords

Homocysteine; Ischaemic heart disease; Long term effects; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY CARE UNIT; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATICS; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL; VITAMIN BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VITAMIN B 12 DEFICIENCY;

EID: 33751033923     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093746     Document Type: Article

References (12)

1. Taylor BV, Oudit GY, Evans M: Homocysteine, vitamins and coronary artery disease; comprehensive review of the literature. Can Fam Physician 2000;46:2236-2245.
2. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-1208.
3. Medrano MJ, Sierra MJ, Almazan J, Olalla MT, Lopez-Abente G: The association of dietary folate, B6, and B12 with cardiovascular mortality in Spain: an ecological analysis. Am J Public Health 2000;90:1636-1638.
4. Hung J, Beilby JP, Knuiman MW, Divitini M: Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. BMJ 2003;326:131-136.
5. Clarke R, Collins R, Lewington S, Donald A, Alfthan G, Tuomilehto J, et al: Homocysteine as risk of heart disease and stroke; a meta-analysis. JAMA 2002;288:2015-2023.
6. De Bree A, Verschuren WM, Blom HJ, Nadeau M, Trijbels FJ, Kromhout D: Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003;166:369-377.
7. Lim HS, Heo YR: Plasma total homocysteine, folate, and vitamin B12 status in Korean adults. J Nutr Sci Vitaminol (Tokyo) 2002;48:290-297.
8. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimburger O, Lindholm B, Bergstrom J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-1735.
9. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554-2558.
10. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang C-H, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
11. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
12. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.